Targeting lymphotoxin depletes pathogenic T cells.
Hansen
Anna M
AM
Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.
Caspi
Rachel R
RR
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000276:immunology / Q000628:therapy*; D006801:Humans; D020381:Interleukin-17 / Q000502:physiology*; D008212:Lymphocyte Depletion; D008233:Lymphotoxin-alpha / Q000037:antagonists & inhibitors*; D018417:Th1 Cells / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D020381:Interleukin-17; D008233:Lymphotoxin-alpha; D014409:Tumor Necrosis Factor-alpha